Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination with Pebolizumab and Albumin Paclitaxel in First-line Treatment of Patients with Unresectable/metastatic Mucosal Melanoma

NCT05420324 is registered in ClinicalTrials.gov with Eucure (Beijing) Biopharma Co., Ltd as lead sponsor.

NCT NCT05420324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination with Pebolizumab and Albumin Paclitaxel in First-line Treatment of Patients with Unresectable/metastatic Mucosal Melanoma
Lead sponsor
Eucure (Beijing) Biopharma Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2022
Completion date
March 4, 2024
Enrollment
20 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

mucosal melanoma